Journal of affective disorders · 2008
Attrition factors in clinical trials of comorbid bipolar and substance-related disorders.
Сравнительное исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nomamiukor Nicole, Brown E Sherwood
Аннотация
BACKGROUND: This study analyzed and defined specific factors that account for attrition in clinical research for patients with bipolar and substance-related disorders.
METHODS: Data were analyzed from two completed studies: an open-label trial of lamotrigine in patients with bipolar disorder (BPD) and cocaine-related disorder, and a placebo-controlled trial of quetiapine in patients with BPD and alcohol-related disorders. Correlations and Independent sample t-tests were performed to assess the impact of baseline characteristics including on length of study participation. Significance was set at the p=0.05 level.
RESULTS: In the lamotrigine-treated patients, the presence of an amphetamine-related disorder, in addition to cocaine-related disorders, was associated with a shorter time in the study. In the quetiapine-treated patients higher scores on the Addiction Severity Index Legal subscale were associated with shorter length in the study. The presence of panic disorder was associated with shorter time in both studies.
LIMITATIONS: Although the data were taken from the two largest clinical trials, to date, in patients with BPD and substance-related disorders, the sample sizes were relatively modest. In addition, the baseline assessments were somewhat different in the two studies limiting our ability to make conclusions on differences between patients with BPD and cocaine use versus alcohol use.
CONCLUSIONS: This study adds to an emerging literature on the significance of panic disorder in patients with BPD.
METHODS: Data were analyzed from two completed studies: an open-label trial of lamotrigine in patients with bipolar disorder (BPD) and cocaine-related disorder, and a placebo-controlled trial of quetiapine in patients with BPD and alcohol-related disorders. Correlations and Independent sample t-tests were performed to assess the impact of baseline characteristics including on length of study participation. Significance was set at the p=0.05 level.
RESULTS: In the lamotrigine-treated patients, the presence of an amphetamine-related disorder, in addition to cocaine-related disorders, was associated with a shorter time in the study. In the quetiapine-treated patients higher scores on the Addiction Severity Index Legal subscale were associated with shorter length in the study. The presence of panic disorder was associated with shorter time in both studies.
LIMITATIONS: Although the data were taken from the two largest clinical trials, to date, in patients with BPD and substance-related disorders, the sample sizes were relatively modest. In addition, the baseline assessments were somewhat different in the two studies limiting our ability to make conclusions on differences between patients with BPD and cocaine use versus alcohol use.
CONCLUSIONS: This study adds to an emerging literature on the significance of panic disorder in patients with BPD.
Предметные рубрики MeSH
AdultAlcohol-Related DisordersAmphetamine-Related DisordersAnticonvulsantsAntipsychotic AgentsBipolar DisorderClinical Trials as TopicCocaine-Related DisordersComorbidityDiagnosis, Dual (Psychiatry)DibenzothiazepinesFemaleHumansLamotrigineMalePanic DisorderPatient DropoutsPsychiatric Status Rating ScalesQuetiapine FumarateRandomized Controlled Trials as TopicSeverity of Illness IndexSubstance-Related DisordersTime FactorsTriazines